Lanreotide and Keytruda – the PLANET study (NCT03043664)


Headline:  Roughly 40% of patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with pembrolizumab (Keytruda) in combination with lanreotide (Somulatine Depot) achieved stable disease, according to results from the phase 1b/2 PLANET clinical trial presented during the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.

I’ve written about Pembrolizumab (Keytruda) before in my general immunotherapy coverage – click here.  I did note they weren’t really having much luck with Neuroendocrine Neoplasms although I do see some success (…. but not enough) in poorly differentiated carcinomas.  Well differentiated NETs remain an immunological desert.  However, this poster abstract from ASCO GI conference caught my eye.

Pembrolizumab has antitumor activity in a subset of GEP-NETs patients,” wrote the investigators. “We hypothesized that the lanreotide, by its antitumor effects and reduction of serotonin, a modulator of immunity, would synergize with pembrolizumab in low/intermediate grade GEP-NETs,” wrote the author led by Michael Morse, MD, of Duke Cancer Center.

In the PLANET study (NCT03043664), 22 patients with GEP-NETs who received a median of 2 prior systemic therapies (range 1-9) were treated with 90 mg of lanreotide and 200 mg of pembrolizumab every 3 weeks until disease progression or intolerable toxicity. A median of 6 doses of pembrolizumab (range, 2-15) and 7 doses of lanreotide (range, 2-15) were administered.

Median age at the time of enrollment was 60.9 years (range, 51.1-82.0). Twelve of the patients were male, and 10 were female. To be eligible for the study, participants were required to have a diagnosis of non-resectable, recurrent, or metastatic well- or moderately-differentiated GEP-NETs with disease progression in the last 12 months, received prior somatostatin analogue therapy, a minimum of 1 measurable lesion based on RECIST 1.1 criteria, an ECOG performance status of 0 or 1, adequate organ function, and a tumor mitotic rate of ≤20/10 hpf and/or Ki67 index ≤20%.
Fourteen patients (63.6%) had tumors located within the gastrointestinal tract, of whom 8 patients (36.4%) had their primary tumor site located in the pancreas. The median time since diagnosis for all patients was 5.3 years, with 6 patients having received prior locoregional therapy and 3 patients receiving prior external beam therapy. Of the 12 tumors that were analyzed, 4 had detectable PD-L1 expression and 11 had tumor infiltrating lymphocytes.

PD-L1 expression on a tumour’s cell is one of the mechanisms of immune evasion, since this inhibits functional activity of cytotoxic lymphocytes which will then not attack tumour cells. Tumor-infiltrating lymphocytes are white blood cells that have left the bloodstream and migrated towards a tumour.

The primary end point of the study was overall response rate (ORR), measured according to RECIST 1.1 criteria. Thirty-nine percent of patients showed stable disease (SD) and 52% of patients had progressive disease (PD). ORR, as measured by irRECIST to better assess the effect of immunotherapeutic agents, was 43% SD, 48% PD, with 9% of patients not evaluable.

Secondary end points were progression-free survival (PFS) and overall survival (OS). The median PFS was 5.4 months (95% CI, 1.7-8.3) and median OS at a median follow-up of 15 months was not reached.

Regarding safety, 6 of the 22 patients (27.3%) experienced treatment-related serious adverse events (AEs) including abdominal pain, pneumonitis, colitis, and hyperglycemia, which were all related to treatment with pembrolizumab. The most common treatment-related AE was hypothyroidism (23%), with other notable treatment-related AEs including colitis (9%), hyperglycemia (14%), and pneumonitis (5%). Three patients (13.6%) discontinued treatment due to AEs. No new safety signals were identified in the study. Investigators noted that peripheral blood immune analyses were pending and would be reported subsequently.

“Further studies to identify other approaches to increase the immunogenicity of well/moderately differentiated GEP-NETs are required,” concluded the investigators.


Morse M, Halperin DM, Uronis HE, et al. Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET). Presented at: 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. January 15–17, 2021; virtual. Abstract 369.

Please note that the results have been appended to the Clinical Trial doc referenced above.  The trial is showing as active but not recruiting and that’s most likely because they are assessing whether they can proceed to the next phase.  I will keep this blog live to bring you details when they are published. 

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 


Subscribe to my newsletter

Thanks for reading.


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


RonnyAllan.NET – Summary of January 2023 – Ronny Allan – Living with Neuroendocrine Cancer

Summary Great start to 2023 and I thank those who continue to support my social media and this blog.  I’m keen to hear any suggestions

Read More »

Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies (incl NET)

Trial Summary This interesting trial is a multi-cancer effort including NET.  The phase I clinical trial of Procaspase Activating Compound-1 (PAC-1), a drug that spurs

Read More »

Dustin Diamond

I’m behind the curve on this one after being ahead on celebrities such as Steve Jobs, Aretha Franklin, Wilko Johnson and Olivia Williams.  But in

Read More »

Neuroendocrine tumors are uncommon but definitely not rare

USA finally commits  UK and Australian figures recently confirmed that Neuroendocrine Cancer is the 10th and 7th most common cancer type.  It was great to

Read More »

Cancer Ablation

What is Cancer Ablation? This is a minimally invasive surgical method to treat solid cancers. Special probes are used to “burn” or “freeze” cancers. Computed

Read More »

Lactose intolerance – the NET Effect

Background   When I cast my mind back to my very first surgery, I remember asking my Oncologist what I could do to put on weight. 

Read More »

EUS Guided Ablation for small pancreatic NETs (Less than 2cm)

To burn or not to burn? I once wrote a post about Pancreatic NET “to cut or not to cut”.  You can read that here. 

Read More »

RonnyAllan.NET – a review of 2022

Review In 2022, my pet project (my blog) hit 2 million views in early November – that was a major boost.  It takes 3-4 years to get

Read More »

RonnyAllan.NET – Summary of December 2022

Summary December is always the quietest month of the year, no surprise why!  However, the top 10 below is somewhat surprising, I guess some posts

Read More »

I love comments - feel free!

%d bloggers like this: